Zambon completes "transformational" acquisition

Privately-held Italian drugmaker Zambon has announced what it describes as a “transformational” acquisition of Germany-based Breath Therapeutics and its subsidiaries from current owner Sofinnova Partners, a leading European venture capital company.

The transaction involves an initial payment of 140 million euros ($156 million), with up to total 500 million euros subject to regulatory and sales milestones.

The combination will improve both companies’ ability to better serve patients and healthcare professionals in severe respiratory diseases, as well as accelerate the commercialization of these important new therapies, said Zambon.